Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 22INDUSTRY 2NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pain Related to Cancer 1Opioid-Related Disorders 1Lymphoma, Follicular 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Methadone × Clear all
NCT01793480 2024-10-31

EQUIMETH2

RECORDATI GROUP

Phase 3 Completed
146 enrolled

Pain Related to Cancer

NCT05251376 2023-01-19

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

Lyndra Inc.

Phase 1 Withdrawn
Lymphoid

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡